Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals (NASDAQ: IONS) lost 11% of its market value after commercialization partner Biogen (NASDAQ: BIIB) reported third-quarter sales of its drug, Spinraza, that failed to match industry watchers' forecasts. Is Ionis Pharmaceuticals' tumble a sign that investors should sell, or a buying opportunity?
Ionis Pharmaceuticals and Biogen are collaboration partners on Spinraza, a drug used to treat spinal muscular atrophy (SMA), a rare life-threatening disease.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
GSK plc ADR Stock
€38.20
0.000%
Currently there is a rather positive sentiment for GSK plc ADR with 4 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 35 € is below the current price of 38.2 € for GSK plc ADR, so the potential is actually -8.38%.
